Form 4: Generation Bio Co. Director Acquires Stock Options

Anthony G. Quinn, a director of Generation Bio Co., was granted stock options to purchase 60,000 shares of common stock at $3.32 per share on June 6, 2024.

Summary

• On June 6, 2024, Anthony G. Quinn, a director of Generation Bio Co., acquired stock options.
• The options grant him the right to purchase 60,000 shares of Generation Bio Co.'s common stock at an exercise price of $3.32 per share.
• The options vest fully on the earlier of June 6, 2025, or the date of Generation Bio's 2025 annual meeting of stockholders.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The granting of stock options is generally viewed as a positive sign, aligning director interests with shareholders, but it's a routine event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• Comparable companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options as part of their director compensation.

Stakeholder Impact

• The granting of stock options could potentially align the director's interests more closely with those of the shareholders.

Key Dates